Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases
Brian S. Gerstenberger, Catherine M. Ambler, Eric P. Arnold, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 22, pp. 13561-13577
Closed Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Protein kinases: drug targets for immunological disorders
Leslie Castelo‐Soccio, Hanna Kim, Massimo Gadina, et al.
Nature reviews. Immunology (2023) Vol. 23, Iss. 12, pp. 787-806
Open Access | Times Cited: 54
KLIFS: an overhaul after the first 5 years of supporting kinase research
Georgi K. Kanev, Chris de Graaf, Bart A. Westerman, et al.
Nucleic Acids Research (2020) Vol. 49, Iss. D1, pp. D562-D569
Open Access | Times Cited: 125
Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis
James G. Krueger, Iain B. McInnes, Andrew Blauvelt
Journal of the American Academy of Dermatology (2021) Vol. 86, Iss. 1, pp. 148-157
Open Access | Times Cited: 77
JAK inhibitors: Ten years after
Francesca Romana Spinelli, Françoise Meylan, John J. O′Shea, et al.
European Journal of Immunology (2021) Vol. 51, Iss. 7, pp. 1615-1627
Open Access | Times Cited: 75
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study
Christopher Tehlirian, Ravi Shankar Prasad Singh, Vivek Pradhan, et al.
Journal of the American Academy of Dermatology (2022) Vol. 87, Iss. 2, pp. 333-342
Open Access | Times Cited: 41
Tyk2 Targeting in Immune-Mediated Inflammatory Diseases
Lluís Rusiñol, L. Puig
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3391-3391
Open Access | Times Cited: 39
Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279
Silvana Leit, Jeremy R. Greenwood, Samantha Carriero, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10473-10496
Closed Access | Times Cited: 25
Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa
Alexa B. Kimball, Elena Peeva, Seth Forman, et al.
NEJM Evidence (2024) Vol. 3, Iss. 3
Closed Access | Times Cited: 13
TYK2: an emerging therapeutic target in rheumatic disease
Eric F. Morand, Joseph F. Merola, Yoshiya Tanaka, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 4, pp. 232-240
Closed Access | Times Cited: 13
Small molecule drug discovery targeting the JAK-STAT pathway
You Lv, Pengbing Mi, Jeffrey J. Babon, et al.
Pharmacological Research (2024) Vol. 204, pp. 107217-107217
Open Access | Times Cited: 12
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2
Chunjian Liu, James C. Lin, Charles M. Langevine, et al.
Journal of Medicinal Chemistry (2020) Vol. 64, Iss. 1, pp. 677-694
Closed Access | Times Cited: 56
A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?
Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, et al.
Arthritis & Rheumatology (2021) Vol. 73, Iss. 12, pp. 2166-2178
Open Access | Times Cited: 51
Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise
Silvio Danese, Laurent Peyrin‐Biroulet
Inflammatory Bowel Diseases (2021) Vol. 27, Iss. 12, pp. 2023-2030
Open Access | Times Cited: 48
Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
Przemysław Kotyla, Małgorzata Engelmann, Joanna Giemza-Stokłosa, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2449-2449
Open Access | Times Cited: 47
Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors
George Martin
Dermatology and Therapy (2023) Vol. 13, Iss. 2, pp. 417-435
Open Access | Times Cited: 21
TYK2 as a Therapeutic Target in the Treatment of Autoimmune and Inflammatory Diseases
Maciej Gonciarz, Katarzyna Pawlak‐Buś, Piotr Leszczyński, et al.
Immunotherapy (2021) Vol. 13, Iss. 13, pp. 1135-1150
Closed Access | Times Cited: 38
Natural and Nature-Derived Products Targeting Human Coronaviruses
Konstantina Vougogiannopoulou, Angela Corona, Enzo Tramontano, et al.
Molecules (2021) Vol. 26, Iss. 2, pp. 448-448
Open Access | Times Cited: 34
Discovery of a Highly Potent and Selective Tyrosine Kinase 2 (TYK2) Degrader with In Vivo Therapeutic Efficacy in a Murine Psoriasis Model
Shuangshuang Xiong, Jiaqi Yang, Ming Yang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019–2021)
Felix González-López de Turiso, Kevin M. Guckian
Expert Opinion on Therapeutic Patents (2022) Vol. 32, Iss. 4, pp. 365-379
Closed Access | Times Cited: 19
Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways
Yu Zhou, Xin Li, Ru Shen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 19
Current application status and structure–activity relationship of selective and non-selective JAK inhibitors in diseases
Tong Li, Xianjing Yang, Juan Zhu, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110660-110660
Closed Access | Times Cited: 12
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study
Christopher Tehlirian, Elena Peeva, Elizabeth Kieras, et al.
The Lancet Rheumatology (2020) Vol. 3, Iss. 3, pp. e204-e213
Closed Access | Times Cited: 28
TYK2 in Cancer Metastases: Genomic and Proteomic Discovery
Dana C. Borcherding, Kevin He, Neha V. Amin, et al.
Cancers (2021) Vol. 13, Iss. 16, pp. 4171-4171
Open Access | Times Cited: 25
TYK2 in Immune Responses and Treatment of Psoriasis
Lin Shang, Jiali Cao, Siqi Zhao, et al.
Journal of Inflammation Research (2022) Vol. Volume 15, pp. 5373-5385
Open Access | Times Cited: 16
Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors
Kuojun Zhang, Ke Ye, He Tang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 4378-4416
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top